HRP20231578T1 - Molekule protutijela na april i njihove uporabe - Google Patents

Molekule protutijela na april i njihove uporabe Download PDF

Info

Publication number
HRP20231578T1
HRP20231578T1 HRP20231578TT HRP20231578T HRP20231578T1 HR P20231578 T1 HRP20231578 T1 HR P20231578T1 HR P20231578T T HRP20231578T T HR P20231578TT HR P20231578 T HRP20231578 T HR P20231578T HR P20231578 T1 HRP20231578 T1 HR P20231578T1
Authority
HR
Croatia
Prior art keywords
antibody molecule
april
molecule
preparation
light chain
Prior art date
Application number
HRP20231578TT
Other languages
English (en)
Inventor
James R. Myette
Zachary Holmes Shriver
Karthik Viswanathan
Andrew M. WOLLACOTT
Hedy ADARI-HALL
Boopathy Ramakrishnan
Gregory Babcock
Original Assignee
Visterra, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visterra, Inc. filed Critical Visterra, Inc.
Publication of HRP20231578T1 publication Critical patent/HRP20231578T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)

Claims (22)

1. Anti-APRIL molekula protutijela, naznačena time, da sadrži varijabilnu regiju teškog lanca (VH) koja ima aminokiselinski slijed SEQ ID NO: 296, i varijabilnu regiju lakog lanca (VL) koja ima aminokiselinski slijed SEQ ID NO: 286.
2. Molekula protutijela prema patentnom zahtjevu 1, naznačena time, da je to sintetička ili izolirana molekula protutijela, i/ili je humanizirana molekula protutijela.
3. Molekula protutijela prema bilo kojem od patentnih zahtjeva 1-2, naznačena time, da sadrži konstantnu regiju teškog lanca od IgG1, IgG2, IgG3, ili IgG4, i/ili sadrži konstantnu regiju lakog lanca od kapa ili lambda lakog lanca.
4. Molekula protutijela prema bilo kojem od patentnih zahtjeva 1-3, naznačena time, da sadrži konstantnu regiju teškog lanca od IgG2.
5. Molekula protutijela prema patentnom zahtjevu 4, naznačena time, da sadrži konstantnu regiju lakog lanca od kapa.
6. Molekula protutijela prema bilo kojem od patentnih zahtjeva 1-5, naznačena time, da sadrži Fc regiju.
7. Molekula protutijela prema bilo kojem od patentnih zahtjeva 1-6, naznačena time, da sadrži dvije varijabilne regije teškog lanca i dvije varijabilne regije lakog lanca, ili je to Fab, F(ab')2, Fv, Fd, ili Fv fragment jednostrukog lanca (scFv).
8. Farmaceutski pripravak, naznačen time, da sadrži molekulu protutijela prema bilo kojem od patentnih zahtjeva 1-7, i farmaceutski prihvatljiv nosač.
9. Molekula nukleinske kiseline, naznačena time, da kodira varijabilnu regiju teškog lanca (VH) i varijabilnu regiju lakog lanca (VL) od molekule protutijela prema bilo kojem od patentnih zahtjeva 1-7.
10. Vektor, naznačen time, da sadrži molekulu nukleinske kiseline prema patentnom zahtjevu 9.
11. Izolirana stanica, naznačena time, da sadrži (i) molekulu nukleinske kiseline prema patentnom zahtjevu 9, (ii) molekulu nukleinske kiseline koja kodira varijabilnu regiju teškog lanca (VH) i molekulu nukleinske kiseline koja kodira varijabilnu regiju lakog lanca (VL), od molekule protutijela prema bilo kojem od patentnih zahtjeva 1-7, ili (iii) vektor prema patentnom zahtjevu 10.
12. Komplet, naznačen time, da obuhvaća molekulu protutijela prema bilo kojem od patentnih zahtjeva 1-7, upute za uporabu molekule protutijela, i jedan ili više od sljedećih: reagens koji je oznaka, terapijsko sredstvo, i uređaj ili materijali za primjenu na pojedincu; te opcionalno nadalje sadrži farmaceutski prihvatljiv nosač.
13. Spremnik, naznačen time, da sadrži molekulu protutijela prema bilo kojem od patentnih zahtjeva 1-7, ili pripravak prema patentnom zahtjevu 8.
14. Postupak za proizvodnju anti-APRIL molekule protutijela, naznačen time, da postupak obuhvaća uzgoj stanice prema patentnom zahtjevu 11, pod uvjetima koji dopuštaju proizvodnju molekule protutijela, gdje se ovim putem proizvodi molekula protutijela.
15. Postupak prema patentnom zahtjevu 14, naznačen time, da nadalje obuhvaća izoliranje ili pročišćavanje molekule protutijela.
16. Molekula protutijela prema bilo kojem od patentnih zahtjeva 1-7, ili pripravak prema patentnom zahtjevu 8, naznačeni time, da su za uporabu u postupku za liječenje IgA nefropatije kod pojedinca.
17. Molekula protutijela za uporabu prema patentnom zahtjevu 16, ili pripravak za uporabu prema patentnom zahtjevu 16, naznačeni time, da se molekula protutijela daje pojedincu intravenozno ili supkutano, i/ili se daje pojedincu u dozi između 0,1 mg/kg i 50 mg/kg, između 0,2 mg/kg i 25 mg/kg, između 0,5 mg/kg i 10 mg/kg, između 0,5 mg/kg i 5 mg/kg, između 0,5 mg/kg i 3 mg/kg, između 0,5 mg/kg i 2,5 mg/kg, između 0,5 mg/kg i 2 mg/kg, između 0,5 mg/kg i 1,5 mg/kg, između 0,5 mg/kg i 1 mg/kg, između 1 mg/kg i 1,5 mg/kg, između 1 mg/kg i 2 mg/kg, između 1 mg/kg i 2,5 mg/kg, između 1 mg/kg i 3 mg/kg, između 1 mg/kg i 10 mg/kg, između 1 mg/kg i 15 mg/kg, ili između 1 mg/kg i 5 mg/kg, ili 1 mg/kg, 2 mg/kg, 4 mg/kg, 6 mg/kg, ili 8 mg/kg, ili u nepromjenjivoj dozi između 10 mg i 1000 mg, između 10 mg i 500 mg, između 10 mg i 250 mg, između 10 mg i 150 mg, između 10 mg i 100 mg, između 10 mg i 50 mg, između 250 mg i 500 mg, između 150 mg i 500 mg, između 100 mg i 500 mg, između 50 mg i 500 mg, između 25 mg i 250 mg, između 50 mg i 150 mg, između 50 mg i 100 mg, između 100 mg i 150 mg, između 100 mg i 200 mg, ili između 150 mg i 250 mg.
18. Molekula protutijela za uporabu prema patentnom zahtjevu 17, ili pripravak za uporabu prema patentnom zahtjevu 17, naznačeni time, da se molekula protutijela daje jednom tjedno, dva puta tjedno, jednom svaka dva tjedna, ili jednom svaka četiri tjedna, ili jednom mjesečno, jednom svaka dva mjeseca, ili jednom svaka tri mjeseca.
19. Molekula protutijela za uporabu prema bilo kojem od patentnih zahtjeva 16-18, ili pripravak za uporabu prema bilo kojem od patentnih zahtjeva 16-18, naznačeni time, da spomenuti postupak nadalje obuhvaća utvrđivanje razine IgA u uzorku perifernog tkiva od pojedinca.
20. Molekula protutijela za uporabu prema patentnom zahtjevu 19, ili pripravak za uporabu prema patentnom zahtjevu 19, naznačeni time, da se kod perifernog tkiva radi o serumu, mukoznom tkivu, ili koštanoj srži.
21. Postupak otkrivanja APRIL molekule, naznačen time, da postupak obuhvaća dovođenje u doticaj stanice ili uzorka od pojedinca s molekulom protutijela prema bilo kojem od patentnih zahtjeva 1-7, čime se otkriva APRIL molekula, dok se pritom APRIL molekula otkriva in vitro ili ex vivo.
22. Postupak otkrivanja APRIL molekule prema patentnom zahtjevu 21, naznačen time, da se molekula protutijela spaja s oznakom koja se može otkriti.
HRP20231578TT 2015-11-25 2016-11-23 Molekule protutijela na april i njihove uporabe HRP20231578T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562259897P 2015-11-25 2015-11-25
US201662313684P 2016-03-25 2016-03-25
US201662399087P 2016-09-23 2016-09-23
US201662422848P 2016-11-16 2016-11-16
PCT/US2016/063518 WO2017091683A1 (en) 2015-11-25 2016-11-23 Antibody molecules to april and uses thereof
EP16810195.4A EP3380522B1 (en) 2015-11-25 2016-11-23 Antibody molecules to april and uses thereof

Publications (1)

Publication Number Publication Date
HRP20231578T1 true HRP20231578T1 (hr) 2024-03-15

Family

ID=57543212

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20231578TT HRP20231578T1 (hr) 2015-11-25 2016-11-23 Molekule protutijela na april i njihove uporabe

Country Status (27)

Country Link
US (8) US20170145086A1 (hr)
EP (2) EP4285923A3 (hr)
JP (4) JP2019506363A (hr)
KR (1) KR20180091849A (hr)
CN (3) CN118027201A (hr)
AU (2) AU2016361488B2 (hr)
BR (1) BR112018010673A8 (hr)
CA (1) CA3006058A1 (hr)
CL (2) CL2018001372A1 (hr)
CO (1) CO2018006461A2 (hr)
DK (1) DK3380522T5 (hr)
ES (1) ES2970864T3 (hr)
FI (1) FI3380522T3 (hr)
HK (1) HK1254337A1 (hr)
HR (1) HRP20231578T1 (hr)
HU (1) HUE064791T2 (hr)
IL (2) IL259585B1 (hr)
LT (1) LT3380522T (hr)
MA (1) MA43308A (hr)
MX (2) MX2018006385A (hr)
MY (1) MY197345A (hr)
PL (1) PL3380522T3 (hr)
PT (1) PT3380522T (hr)
SA (1) SA518391659B1 (hr)
SG (1) SG11201804309PA (hr)
SI (1) SI3380522T1 (hr)
WO (1) WO2017091683A1 (hr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210340266A1 (en) * 2008-10-09 2021-11-04 Visterra, Inc. Antibody molecules to april and uses thereof
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
KR20160115953A (ko) 2014-01-31 2016-10-06 다나-파버 캔서 인스티튜트 인크. 디아미노피리미딘 벤젠술폰 유도체 및 그의 용도
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体の使用
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
PE20181086A1 (es) 2015-09-11 2018-07-05 Dana Farber Cancer Inst Inc Acetamida tienotrizolodiazepinas y usos de las mismas
CA2996974A1 (en) 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
HUE064791T2 (hu) 2015-11-25 2024-04-28 Visterra Inc APRIL ellenes antitest molekulák és alkalmazásaik
EP3380100A4 (en) 2015-11-25 2019-10-02 Dana-Farber Cancer Institute, Inc. BIVALENT BROMODOMAIN INHIBITORS AND USES THEREOF
EA202191783A1 (ru) * 2018-12-24 2021-11-16 Вистерра, Инк. Способы определения эпитопов и паратопов
AU2020225631A1 (en) * 2019-02-22 2021-09-16 Memorial Sloan Kettering Cancer Center CD33 antibodies and methods of using the same to treat cancer
CN110522902B (zh) * 2019-09-25 2022-10-11 南京农业大学 一种用于建立慢性肾病模型的组合物及其应用
CA3175134A1 (en) * 2020-03-13 2021-09-16 Janssen Biotech, Inc. Materials and methods for modulating delta chain mediated immunity
TW202216195A (zh) 2020-06-24 2022-05-01 美商威特拉公司 April抗體分子及其用途
US20220110894A1 (en) * 2020-10-13 2022-04-14 Accubit LLC - Biotechnology Methods of Treating IgA Nephropathy with Thiol-Containing Molecules
CA3199767A1 (en) 2020-10-28 2022-05-05 Janssen Biotech, Inc. Compositions and methods for modulating delta gamma chain mediated immunity
CN112730851B (zh) * 2021-03-31 2021-06-22 南京立顶医疗科技有限公司 一种高灵敏SARS-CoV-2中和抗体的检测方法、检测试剂盒
KR20240004838A (ko) * 2021-05-04 2024-01-11 임뮤노라이즌 엘티디. 항-nkg2d 항체 및 이의 용도
CA3216795A1 (en) 2021-05-07 2022-11-10 Alpine Immune Sciences, Inc. Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
TW202342548A (zh) 2022-02-07 2023-11-01 美商威特拉公司 抗獨特型(anti-idiotype)抗體分子及其用途
US20240092921A1 (en) * 2022-04-25 2024-03-21 Visterra, Inc. Antibody molecules to april and uses thereof
WO2024077018A2 (en) 2022-10-04 2024-04-11 Alpine Immune Sciences, Inc. Methods and uses of taci-fc fusion immunomodulatory protein

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5612205A (en) 1990-08-29 1997-03-18 Genpharm International, Incorporated Homologous recombination in mammalian cells
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
DK1279731T3 (da) 1991-03-01 2007-09-24 Dyax Corp Fremgangsmåde til udvikling af bindende miniproteiner
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP2192131A1 (en) 1992-08-21 2010-06-02 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
BR9812634A (pt) 1997-09-12 2000-08-22 Biogen Inc April - uma proteìna com efeitos de crescimento
WO2001060397A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU2001261557B2 (en) 2000-05-12 2005-06-30 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
EP1401870A4 (en) 2001-05-24 2006-04-19 Human Genome Sciences ANTIBODIES AGAINST TUMOR NECROSIS FACTOR DELTA (APRIL)
AU2004315198A1 (en) 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of BCMA and uses thereof
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
DE602006020467D1 (de) * 2005-09-26 2011-04-14 Enzo Life Sciences Els Ag Antikörper gegen april als biomarker zur frühen prognose in lymphompatienten
WO2008119042A2 (en) 2007-03-27 2008-10-02 Zymogenetics, Inc. Combination of blys inhibition and/or april inhibition and immunnosuppressants for treatment of autoimmune disease
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
JP5314033B2 (ja) * 2007-10-22 2013-10-16 メルク セローノ ソシエテ アノニム 突然変異ＩｇＧＦｃフラグメントと融合した単一ＩＦＮ−ベータ
JP5902478B2 (ja) * 2008-05-01 2016-04-13 ザイモジェネティクス， インコーポレイテッド 血清中のＢＬｙＳ／ＡＰＲＩＬヘテロ三量体レベルおよび診断方法における使用
US20210340266A1 (en) 2008-10-09 2021-11-04 Visterra, Inc. Antibody molecules to april and uses thereof
HUE027826T2 (en) 2009-03-02 2016-11-28 Aduro Biotech Holdings Europe B V Anti-proliferative Ligand Antibodies (APRIL)
US20120201823A1 (en) * 2009-10-14 2012-08-09 Schering Corporation April antagonists and methods of use
EA201890907A1 (ru) * 2009-11-30 2020-04-30 Янссен Байотек, Инк. МУТИРОВАННЫЕ Fc АНТИТЕЛА С УСТРАНЕННЫМИ ЭФФЕКТОРНЫМИ ФУНКЦИЯМИ
CA2810465C (en) * 2010-09-16 2018-10-02 Baliopharm Ag Anti-hutnfr1 antibody
EP2699264B1 (en) 2011-04-20 2018-03-14 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
PT3415531T (pt) * 2011-05-27 2023-09-12 Glaxo Group Ltd Proteínas de ligação a bcma (cd269/tnfrsf17
RU2616881C2 (ru) * 2011-06-06 2017-04-18 Ново Нордиск А/С Терапевтические антитела
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US9243058B2 (en) 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
EA201591806A1 (ru) * 2013-03-15 2016-01-29 Байоджен Ма Инк. Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
WO2015069865A1 (en) * 2013-11-06 2015-05-14 Janssen Biotech, Inc. Anti-ccl17 antibodies
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
EP3245230B1 (en) 2015-01-15 2020-12-16 Université Grenoble Alpes Anti april (a proliferation-inducing ligand) antibodies and their uses for the prognosis and/or diagnosis of cancer
HUE064791T2 (hu) 2015-11-25 2024-04-28 Visterra Inc APRIL ellenes antitest molekulák és alkalmazásaik
CN105390742A (zh) * 2015-12-31 2016-03-09 石家庄圣泰化工有限公司 高电压锂离子电池电解液及其制备方法及应用
WO2020144535A1 (en) 2019-01-08 2020-07-16 Aduro Biotech Holdings, Europe B.V. Methods and compositions for treatment of multiple myeloma
TW202216195A (zh) 2020-06-24 2022-05-01 美商威特拉公司 April抗體分子及其用途
TW202342548A (zh) 2022-02-07 2023-11-01 美商威特拉公司 抗獨特型(anti-idiotype)抗體分子及其用途
US20240092921A1 (en) 2022-04-25 2024-03-21 Visterra, Inc. Antibody molecules to april and uses thereof

Also Published As

Publication number Publication date
DK3380522T5 (da) 2024-09-30
EP4285923A3 (en) 2024-03-06
AU2016361488A1 (en) 2018-06-14
DK3380522T3 (da) 2024-01-22
PT3380522T (pt) 2024-02-14
BR112018010673A2 (pt) 2018-11-13
JP7029018B2 (ja) 2022-03-02
JP2019506363A (ja) 2019-03-07
US20200331995A1 (en) 2020-10-22
US20170145086A1 (en) 2017-05-25
MX2024010175A (es) 2024-08-27
US10385123B2 (en) 2019-08-20
US20190330326A1 (en) 2019-10-31
CO2018006461A2 (es) 2018-08-31
BR112018010673A8 (pt) 2019-02-26
WO2017091683A1 (en) 2017-06-01
MY197345A (en) 2023-06-14
US10954296B2 (en) 2021-03-23
US10981982B2 (en) 2021-04-20
CN118420760A (zh) 2024-08-02
US20220235124A1 (en) 2022-07-28
HUE064791T2 (hu) 2024-04-28
US20210032324A1 (en) 2021-02-04
CN109089419A (zh) 2018-12-25
KR20180091849A (ko) 2018-08-16
US10968270B2 (en) 2021-04-06
US20190092851A1 (en) 2019-03-28
EP3380522B1 (en) 2023-11-08
SA518391659B1 (ar) 2022-12-13
ES2970864T3 (es) 2024-05-31
CA3006058A1 (en) 2017-06-01
US20200317770A1 (en) 2020-10-08
CN118027201A (zh) 2024-05-14
US11136385B2 (en) 2021-10-05
SG11201804309PA (en) 2018-06-28
IL259585B1 (en) 2024-07-01
AU2023201698A1 (en) 2023-04-20
JP2024073611A (ja) 2024-05-29
LT3380522T (lt) 2024-02-26
RU2018122452A (ru) 2019-12-25
IL259585A (en) 2018-07-31
FI3380522T3 (fi) 2024-01-16
CL2018001372A1 (es) 2018-11-23
US12091451B2 (en) 2024-09-17
PL3380522T3 (pl) 2024-03-25
IL313508A (en) 2024-08-01
JP2021184740A (ja) 2021-12-09
CN109089419B (zh) 2024-03-01
CL2024000276A1 (es) 2024-08-30
RU2018122452A3 (hr) 2020-05-13
EP3380522A1 (en) 2018-10-03
SI3380522T1 (sl) 2024-02-29
AU2016361488B2 (en) 2022-12-22
US20200299376A1 (en) 2020-09-24
EP4285923A2 (en) 2023-12-06
MX2018006385A (es) 2019-09-11
HK1254337A1 (zh) 2019-07-19
WO2017091683A8 (en) 2022-12-15
JP2022068288A (ja) 2022-05-09
MA43308A (fr) 2018-10-03

Similar Documents

Publication Publication Date Title
HRP20231578T1 (hr) Molekule protutijela na april i njihove uporabe
HRP20190486T1 (hr) Konjugirani spojevi koji sadrže cisteinska protutijela dobivena inženjeringom
HRP20201975T1 (hr) Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
HRP20201022T1 (hr) Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba
HRP20210375T1 (hr) Virus ljudske imunodeficijencije neutraliziranja antitijela i postupci njegova korištenja
FI3389699T3 (fi) Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja
HRP20200887T1 (hr) Smjese za inhibiciju masp-2 ovisne aktivacije komplementa
IL299072A (en) Antibodies and methods for using them
HRP20200882T1 (hr) Vezujuće molekule specifične za asct2 i njihova uporaba
HRP20181087T1 (hr) Pripravak i postupak dijagnostike i liječenja bolesti povezanih s degeneracijom neurita
JP2013121353A5 (hr)
ES2707599T3 (es) Anticuerpos anti-asic1 y usos de los mismos
BR112019025904A2 (pt) método de fabricação de anticorpos biespecíficos, anticorpos biespecíficos e uso terapêutico de tais anticorpos
JP2018502060A5 (hr)
MY182680A (en) Antibody formulation and therapeutic regimens
UA113728C2 (xx) Фармацевтична композиція, яка містить антитіло до pcsk9 людини
HRP20191129T1 (hr) Anti-klusterinska protutijela i ulomci koji vežu antigen i njihova uporaba za smanjivanje volumena tumora
EP2473191A1 (en) Antibody coformulations
HRP20110334T1 (hr) PROTUTIJELA SPECIFIČNA ZA TGF-ß1
CN106459196A (zh) 抗体、用途和方法
HRP20220918T1 (hr) Anti-transtiretinska antitijela
RU2016123839A (ru) Новые модуляторы и способы их применения
JP2017530092A5 (hr)
WO2017060322A3 (en) Ptefb-inhibitor-adc
ES2905160T3 (es) Inhibidores selectivos de la isoforma TGFBeta1 y utilización de los mismos